ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression

WESTON, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, highlights key data on the role of lipotoxicity in the development and progression of DKD from a review article, Targeting lipid metabolic reprogramming to alleviate diabetic kidney disease: molecular insights and therapeutic strategies, recently published in Frontiers in Immunology. This article, which summarized 172 papers, demonstrated that under diabetic conditions, kidney cells undergo significant lipid metabolic abnormalities resulting in accumulation of lipids that trigger inflammation and fibrosis leading to DKD progression.

Read more at globenewswire.com